## Yi Zhu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4251751/publications.pdf

Version: 2024-02-01

20	7,917	17 h-index	20
papers	citations		g-index
20	20	20	7971
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans. EBioMedicine, 2022, 77, 103912.	6.1	27
2	Mechanisms of vascular dysfunction in the interleukin-10–deficient murine model of preeclampsia indicate nitric oxide dysregulation. Kidney International, 2021, 99, 646-656.	5.2	10
3	Wholeâ€body senescent cell clearance alleviates ageâ€related brain inflammation and cognitive impairment in mice. Aging Cell, 2021, 20, e13296.	6.7	186
4	Senolytics reduce coronavirus-related mortality in old mice. Science, 2021, 373, .	12.6	184
5	Epigenetic and senescence markers indicate an accelerated ageing-like state in women with preeclamptic pregnancies. EBioMedicine, 2021, 70, 103536.	6.1	20
6	Fisetin for <scp>COVID</scp> â€19 in skilled nursing facilities: Senolytic trials in the <scp>COVID</scp> era. Journal of the American Geriatrics Society, 2021, 69, 3023-3033.	2.6	35
7	SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3. Aging, 2021, 13, 21838-21854.	3.1	51
8	Development of a novel senolytic by precise disruption of FOXO4-p53 complex. EBioMedicine, 2021, 74, 103693.	6.1	3
9	Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases. International Review of Neurobiology, 2020, 155, 203-234.	2.0	50
10	Targeting senescent cells alleviates obesityâ€induced metabolic dysfunction. Aging Cell, 2019, 18, e12950.	6.7	395
11	Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis. Cell Metabolism, 2019, 29, 1061-1077.e8.	16.2	293
11	Obesity-Induced Cellular Senescence Drives Anxiety and Impairs Neurogenesis. Cell Metabolism, 2019, 29, 1061-1077.e8.  Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â°'/â°') mice. Hepatology, 2018, 67, 247-259.		293
	29, 1061-1077.e8.  Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â°/lâ^²) mice. Hepatology,	16.2	
12	29, 1061-1077.e8.  Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â°'/â°') mice. Hepatology, 2018, 67, 247-259.	16.2 7.3	99
12	29, 1061-1077.e8.  Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â°/lâ°') mice. Hepatology, 2018, 67, 247-259.  Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 2018, 36, 18-28.	16.2 7.3 6.1	99 554
12 13 14	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€eell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â°'/â°') mice. Hepatology, 2018, 67, 247-259.  Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 2018, 36, 18-28.  Cellular senescence mediates fibrotic pulmonary disease. Nature Communications, 2017, 8, 14532.  New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and	7.3 6.1 12.8	99 554 1,008
12 13 14	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€eell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â"/â") mice. Hepatology, 2018, 67, 247-259.  Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine, 2018, 36, 18-28.  Cellular senescence mediates fibrotic pulmonary disease. Nature Communications, 2017, 8, 14532.  New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging, 2017, 9, 955-963.  The Clinical Potential of Senolytic Drugs. Journal of the American Geriatrics Society, 2017, 65,	7.3 6.1 12.8 3.1	99 554 1,008

#	Article	IF	CITATIONS
19	The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 2015, 14, 644-658.	6.7	1,534
20	Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. Journal of Clinical Investigation, 2013, 123, 966-972.	8.2	1,326